{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:02:55Z","timestamp":1792836175538,"version":"4.5.0"},"reference-count":33,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>A review on the mental health needs of adults with intellectual disability (ID) and autism spectrum disorder (ASD) published just over 10 years ago found a limited evidence base for pharmacological intervention in this group. The aim of this paper was therefore to review the evidence in the subsequent 10 years, with a focus on polypharmacy use in adults who have both ID and ASD. A critical literature review of key papers published from 2009 to 2021 was undertaken on adults with both ID and ASD and related to psychopharmacology, polypharmacy, antipsychotics, antidepressants, mood stabilisers and anxiolytics interventions in improving symptoms. After excluding articles for lack of relevance, a review with a focus on the use of polypharmacy was carried out on the retrieved results. Four papers were identified as relevant to adults with both ID and ASD. Three main themes were identified in the review, including the application of pharmacogenetics, the influence of national policy on prescribing practices and safety concerns in a population with multiple health comorbidities. The past decade has produced a small increase in the evidence base on psychopharmacology use in adults with ID and ASD. However, more evidence on the effectiveness and impact of long-term polypharmacy use is required.<\/jats:p>","DOI":"10.3390\/ijerph192315974","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T03:49:13Z","timestamp":1669780153000},"page":"15974","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Adults with Intellectual Disability and Autism Spectrum Disorder: What Is the Evidence around the Use of Polypharmacy"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4702-1939","authenticated-orcid":false,"given":"Jane M.","family":"McCarthy","sequence":"first","affiliation":[{"name":"Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand"},{"name":"Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London SE5 8AF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2865-1070","authenticated-orcid":false,"given":"Eddie","family":"Chaplin","sequence":"additional","affiliation":[{"name":"Foundation for People with Learning Disabilities, Institute of Health and Social Care, London South Bank University, London SE1 0AA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/YCO.0b013e32833cfc18","article-title":"Mental health of adults with autism spectrum disorders and intellectual disability","volume":"23","author":"Underwood","year":"2010","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.7861\/clinmedicine.16-5-465","article-title":"The epidemiology of polypharmacy","volume":"16","author":"Payne","year":"2016","journal-title":"Clin. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1176\/appi.ps.201700032","article-title":"Predictors of Psychotropic Polypharmacy Among Outpatients With Psychiatric Disorders and Intellectual Disability","volume":"69","author":"Lunsky","year":"2018","journal-title":"Psychiatr. Serv."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jir.12119","article-title":"Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour","volume":"59","author":"Deb","year":"2014","journal-title":"J. Intellect. Disabil. Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bertelli, M.O., Deb, S.S., Munir, K., Hassiotis, A., and Salvador-Carulla, L. (2022). Psychopharmacology. Textbook of Psychiatry for Intellectual Disability and Autism Spectrum Disorder, Springer Nature.","DOI":"10.1007\/978-3-319-95720-3"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1192\/bjp.2021.165","article-title":"Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: Preliminary findings based on a systematic review and dose\u2013effect meta-analysis","volume":"221","author":"Furukawa","year":"2021","journal-title":"Br. J. Psychiatry"},{"key":"ref_7","unstructured":"Sappok, T., and Burtscher, R. (2021). New insights on psychopathological assessment in persons with intellectual disability and low-functioning autism spectrum disorder. Improving Mental Health in Persons with Intellectual Disability\u2014From Science to Practice, Loeper."},{"key":"ref_8","unstructured":"Bertelli, M. (2021). New Insights on Psychopathological Assessment in Persons with Intellectual Disability and Low-Functioning Autism Spectrum Disorder, Wiley."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ridd.2009.10.009","article-title":"Challenging behavior and co-morbid psychopathology in adults with intellectual disability and autism spectrum disorders","volume":"31","author":"McCarthy","year":"2010","journal-title":"Res. Dev. Disabil."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.psychres.2018.10.039","article-title":"Problem behaviours and Major Depressive Disorder in adults with intellectual disability and autism","volume":"270","author":"Baudewijns","year":"2018","journal-title":"Psychiatry Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/19315864.2022.2029641","article-title":"Intellectual Disability, Autism Spectrum Disorders, Psychiatric Comorbidities and Their Relationship with Challenging Behavior","volume":"15","author":"Arrufat","year":"2022","journal-title":"J. Ment. Health Res. Intellect. Disabil."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1741-1130.2012.00343.x","article-title":"Health and Social Functioning of Adults With Intellectual Disability and Autism","volume":"9","author":"Underwood","year":"2012","journal-title":"J. Policy Pr. Intellect. Disabil."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881117741766","article-title":"Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology","volume":"32","author":"Howes","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"ref_14","first-page":"41","article-title":"The introduction of generic risperidone in Medicare Part D","volume":"22","author":"Fung","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(08)60072-0","article-title":"Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: A randomised controlled trial","volume":"371","author":"Tyrer","year":"2008","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(21)01541-5","article-title":"The Lancet Commission on the future of care and clinical research in autism","volume":"399","author":"Lord","year":"2021","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/jir.12471","article-title":"Problem behaviours and psychotropic medication use in intellectual disability: A multinational cross-sectional survey","volume":"62","author":"Perry","year":"2018","journal-title":"J. Intellect. Disabil. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1192\/bjp.2022.34","article-title":"Antidepressant prescribing for adult people with an intellectual disability living in England","volume":"221","author":"Branford","year":"2022","journal-title":"Br. J. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S730","DOI":"10.1016\/S0924-977X(16)31881-8","article-title":"Comorbidities as predictor of polypharmacy in autism spectrum disorder","volume":"26","author":"Ballester","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ridd.2008.08.007","article-title":"Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview","volume":"30","author":"Matson","year":"2009","journal-title":"Res. Dev. Disabil."},{"key":"ref_21","unstructured":"NICE (2014). Developing NICE Guidelines: The Manual, National Institute for Health and Care Excellence."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/0706743720971950","article-title":"Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review","volume":"66","author":"Yoshida","year":"2020","journal-title":"Can. J. Psychiatry"},{"key":"ref_23","unstructured":"Mehta, H., and Glover, G. (2019). Psychotropic Drugs and People with Learning Disabilities or Autism, Public Health."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"113321","DOI":"10.1016\/j.psychres.2020.113321","article-title":"Multimorbidity and psychotropic polypharmacy among participants with autism spectrum disorder with intellectual disability","volume":"292","author":"Espadas","year":"2020","journal-title":"Psychiatry Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3389\/fpsyt.2019.00617","article-title":"Comorbidity Burden in Adults with Autism Spectrum Disorders and Intellectual Disabilities\u2014A Report From the EFAAR (Frailty Assessment in Ageing Adults with Autism Spectrum and Intellectual Disabilities) Study","volume":"10","author":"Miot","year":"2019","journal-title":"Front. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"h4326","DOI":"10.1136\/bmj.h4326","article-title":"Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study","volume":"351","author":"Sheehan","year":"2015","journal-title":"BMJ"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.rasd.2014.03.021","article-title":"Psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities: A systematic review","volume":"8","author":"Sawyer","year":"2014","journal-title":"Res. Autism Spectr. Disord."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Deb, S., Nancarrow, T., Limbu, B., Sheehan, R., Wilcock, M., Branford, D., Courtenay, K., Perera, B., and Shankar, R. (2020). UK psychiatrists\u2019 experience of withdrawal of antipsychotics prescribed for challenging behaviours in adults with intellectual disabilities and\/or autism. BJPsych Open, 6.","DOI":"10.1192\/bjo.2020.97"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/jcph.1271","article-title":"An open-label discontinuation trial of long-term, off-label antipsychotic medication in people with intellectual disability: Determinants of success and failure","volume":"58","author":"Hoekstra","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/jar.12635","article-title":"A structured programme to withdraw antipsychotics among adults with intellectual disabilities: The Cornwall experience","volume":"32","author":"Shankar","year":"2019","journal-title":"J. Appl. Res. Intellect. Disabil."},{"key":"ref_31","unstructured":"Royal College of Psychiatrists (2016). Psychotropic Drug Prescribing for People with Intellectual Disability, Mental Health Problems and\/or Behaviours That Challenge: Practice Guidelines, Royal College of Psychiatrists. Contract No.: FR\/ID\/09."},{"key":"ref_32","first-page":"60","article-title":"Lessons learned from our elders: How to study polypharmacy in populations with intellectual and developmental disabilities","volume":"52","author":"Stortz","year":"2014","journal-title":"Ment. Retard."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Beumer, S., Hamers, P., Oppewal, A., and Maes-Festen, D. (2021). Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: Study protocol for a multicentre double-blind placebo-controlled randomised trial. BMC Psychiatry, 21.","DOI":"10.1186\/s12888-021-03437-2"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/23\/15974\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:30:07Z","timestamp":1760146207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/23\/15974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":33,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["ijerph192315974"],"URL":"https:\/\/doi.org\/10.3390\/ijerph192315974","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}